Purpose: To apply propensity score matching to Ahmed glaucoma drainage implants (AGI) to trabectome-mediated ab interno trabeculectomy (AIT). Recent data suggest that AIT can produce results similar to AGI traditionally reserved for more severe glaucoma.
glaucoma. 1 Like the Krupin glaucoma drainage implant, 2 the first valved glaucoma device, the Ahmed glaucoma drainage implant (AGI, New World Medical, Rancho Cucamonga, CA) has a pressure-sensitive valve designed to open when the intraocular pressure (IOP) is 8 mm Hg to avoid complications related to hypotony during the early postoperative period. 3 In contrast, the Trabectome (Neomedix Inc., Tustin, CA), generates plasma to ablate the trabecular meshwork (TM), 4 which constitutes the primary resistance to outflow. This procedure is called trabectome-mediated ab interno trabeculectomy (AIT). Outflow resistance downstream of the TM and the episcleral venous pressure limit IOP reductions as compared with AGI while also preventing hypotony. 5 Complications are relatively rare and similar to that seen in cataract surgery. 6 AIT also lowers IOP rapidly but has been used only in mild to moderate glaucoma until it was recently described as an option for failed trabeculectomy 7 or failed epibulbar glaucoma drainage implants. 8 AGI and AIT differ considerably in procedure times, cost, 9, 10 and complication profiles. 6, 11 Previous studies of AIT [12] [13] [14] [15] [16] [17] and AGI 11, 18 suggested a similar postoperative average IOP, but the patient populations might have different in glaucoma severity and type. Recent studies that stratified AIT outcomes by glaucoma severity indicated that patients with a higher preoperative IOP and more severe glaucoma experienced a larger IOP reduction. [19] [20] [21] Because of this, we expanded our surgical indications to include those traditionally reserved for AIG and compared the outcomes in the present study. We hypothesized that AIG and AIT achieve a similar pressure reduction when similar glaucoma stages are compared.
Although a randomized controlled trial remains the most effective tool to reduce bias and patient selection, modern statistical matching strategies [22] [23] [24] [25] obtain a highly balanced comparison of already existing patient data. They also avoid nonroutine practice patterns and a potential bias that may occur during patient recruitment in trials. We have used Coarsened Exact Matching before 26, 27 to achieve a balanced comparison, but the challenge with potentially more uneven groups is that only a few patients in each group can be matched precisely. The risk of achieving an overlap of matched features by those means is that regression toward the mean occurs which can make the comparison group look better or worse than they are. In contrast, the method we use here, propensity score matching, uses a predicted probability of group membership to achieve a match. 24, 25, 28 
METHODS
This retrospective chart review was approved by the Institutional Review Board of the University of Pittsburgh (PRO14100026) and adhered to the tenets of the Declaration of Helsinki and the Health Insurance Portability and Accountability Act of 1996. Charts from October 2012 through February 2015 were included that had a follow-up of at least 1 year. Inclusion criteria were at least 18 years of age undergoing AIT or AGI surgery with at least 12 months of follow-up. All surgeries were performed by the same group of surgeons using the same surgical technique. Neovascular glaucoma was excluded.
The main outcome measure was the postoperative IOP at 1 year. Secondary measures included the reduction of medications as well as success rates. Failure was defined [after the tube versus trabeculectomy (TVT)] 29 as anyone of postoperative IOP < 6, IOP > 21 mm Hg, or ≤ 20% reduction in IOP from baseline at 2 consecutive visits after 3 months, or reoperation.
All patients underwent a complete ophthalmologic examination before surgery and at each postoperative visit; this included best-corrected visual acuity, slit-lamp biomicroscopy, Goldmann applanation tonometry, and funduscopic evaluation. The indication for surgery (including the decision of which surgery to proceed with) was determined by the individual surgeon when the IOP was above the targeted IOP on maximally tolerated medical treatment. Procedures were performed by the same group of surgeons on comparable patient populations. The decisions to resume medications or to reoperate were also made by the individual surgeon.
The Glaucoma Index (GI) is an indicator of the severity of glaucoma and its relative resistance to treatment. [19] [20] [21] It is based on the visual field (VF) damage, the number of preoperative glaucoma medications, and the preoperative IOP. VF was separated into 3 categories: mild, moderate, or advanced VF damage, which was assigned 1, 2, or 3 points, respectively. Preoperative number of medications were divided into 4 categories: 0 to 1, 2, 3, or 4+, and assigned a value of 1 to 4, respectively. Baseline IOP was divided into 3 categories: <20, 20 to 29, 30 to 39, and > 40 mm Hg and assigned from 1 to 4 points, respectively. GI was defined as the product of preoperative IOP× preoperative number of medications×VF and separated into 4 groups: <6 (group 1), 6 to 12 (group 2), > 12 to 18 (group 3), and > 18 (group 4).
Statistical Analysis
Cases were matched with propensity score matching (package "Matching" in R) 30 ,31 using a genetic algorithm based on age, sex, type of glaucoma, concurrent phacoemulsification, and baseline IOP and medications. Cases of AIT or AGI too different from their counterparts were excluded. Weighted linear regression was significant when P < 0.05. A Kaplan-Meier survival curve for right-censored data with 80% confidence intervals was computed. A Cox proportional hazard model was developed to estimate the effects of 16, 21, and 26 mm Hg preoperative IOP on surgical success. Data available beyond the 12 months were included in a secondary analysis and shown in average IOPs, medications, survival, and hazard graphs.
Surgical Technique
AIT ( Fig. 1) was performed by creating a 1.8 mm uniplanar temporal clear corneal incision and ablating ∼140 to 160 degrees of nasal TM under direct gonioscopic view. For AIT combined with phacoemulsification, the main incision was enlarged to 2.2 mm followed by a standard phacoemulsification. AGI tubes (model FP-7, Fig. 1 ) were primed and sutured to the superotemporal sclera 10 mm posterior to the surgical limbus. The tube was trimmed to extend 1 to 2 mm onto the anterior surface of the iris and covered with a scleral patch graft.
Patients in both groups used topical moxifloxacin and prednisolone acetate 1% 4 times per day. AIT patients also received pilocarpine 1% 4 times daily for 1 month then 3 times daily for 1 month. All preoperative glaucoma medications were stopped on the day of surgery and were added back later at the discretion of the surgeon. Postoperative clinic visits occurred at day 1, week 1, month 1, month 3, month 6, and month 12.
RESULTS
Of 102 AIT and 49 AGI patients, 66 were included in the study, consisting of 34 individuals in the AIT group and 32 in the AGI group. Using case matching, there was no significant difference in ethnicity, IOP, the number of IOPlowering medications, glaucoma type, the degree of VF loss, and GI between AIT and AGI (P > 0.05). Table 1 shows baseline characteristics of each group. In AIT, 9 patients had previous procedures consisting of 4 cataract surgeries, 1 trabeculectomy, 2 corneal repairs (history of traumatic corneal laceration), and 2 vitrectomies. In AGI, 10 patients had previous procedures consisting of 6 cataract surgeries, 1 trabectome surgery, 1 trabeculectomy, 1 tube shunt, and 1 vitrectomy. The baseline characteristics of excluded cases are presented in Table 2 .
AIT had a preoperative IOP of 23.6 ± 8.1 mm Hg compared with 26.5+10.6 mm Hg in AGI. The mean IOP at 1 week was 15.6 ± 9.8 mm Hg for AIT versus 15.7 ± 7.2 mm Hg for AGI (P = 0.9), 15.6 ± 4.5 mm Hg for AIT versus 16.4 ± 6.4 mm Hg for AGI (P = 0.4) at 3 months. At 6 months, the mean IOP was 13.4 ± 6.2 mm Hg for AIT versus 16.3 ± 5.2 mm Hg for AGI (P = 0.06). At 12 months, the mean IOP was 14.5 ± 8.7 mm Hg for AIT versus 14.9 ± 3.6 mm Hg for AGI (P = 0.8). The average IOP FIGURE 1. Ahmed glaucoma drainage device and trabectome to scale. Devices are shown at the correct relative size and in the same eye for easier comparison. The Ahmed glaucoma drainage device has a valve to prevent overfiltration and a silicone plate with a surface area of 184 mm 2 (left). The trabectome is most commonly inserted through a temporal incision (nasal incision depicted in this illustration), and the trabecular meshwork is ablated along the nasal angle. The tip of the trabectome has a protective footplate that feeds the trabecular meshwork toward the active and passive electrode where plasma is generated (top right). The molecularized tissue is displaced by fluid from the irrigation ports and aspirated at the tip. Figure 1 can be viewed in color online at www.glaucomajournal.com. reduction was 8 mm Hg (30%) and 11 mm Hg (31%) in AIT and AGI, respectively. Figure 2 illustrates the postoperative IOP changes. The number of IOP-lowering medications (Fig. 3 ) at 3 months was 2.7 ± 1.4 for AIT versus 3.6 ± 1.7 (P = 0.02). At 6 months, it was 2.6 ± 1.8 for AIT versus 3.7 ± 1.3 for AGI (P = 0.018). At 1 year, the number of medications was 2.3 ± 2.2 for AIT versus 3.6 ± 1.3 for AGI (P = 0.016).
The survival analysis (Fig. 4) indicated a similar survival for both AIT and AGI. Although the survival declined faster for AIT at 300 days, the difference was insignificant (P = 0.36). Six AIT patients required additional interventions consisting of 2 AGIs and 4 transscleral diode cyclophotocoagulation procedures, respectively. Nine additional procedures were required in the AGI group including 3 AGI revisions, 4 additional Baerveldt glaucoma shunt implantations, and 2 cyclophotocoagulations. The baseline IOP in patients who needed a reoperation was 23.3 mm Hg in AIT and 26.18 mm Hg in Ahmed glaucoma valve group (P = 0.31). Corresponding values for IOPs before the second surgery was 26.8 and 27.17 mm Hg, respectively (P = 0.72).
Cox proportional hazard modeling (Fig. 5 ) was only possible for the preoperative IOP due to the limited number of eyes available for potential covariates. The Cox hazard model for different levels of preoperative IOP suggested that AIT did slightly better, lagging ∼250 to 500 days behind 
Complications
After AIT, the only complication was cystoid macular edema that occurred in a single case (0.8%) which was combined with phacoemulsification. After AGI, there were choroidal effusions in 7%, hypotony past 3 months in 2%, and diplopia in 2%. Visual acuity decreased by ≥ 2 Snellen lines after 1 year in 0% of AIT and 3% of AGI.
DISCUSSION
In this study, we found that AIT and AGI devices achieved a similar IOP reduction. Although AIT is a mature microincisional glaucoma surgery introduced almost 15 years ago, no study has compared trabecular bypass or ablation with traditional glaucoma surgeries. We used propensity score matching to compare AIT, which enhances outflow along the physiological, conventional outflow route and AGI, a valved epibulbar drainage device, which allows bypassing both the conventional and the uveoscleral outflow. Because these surgeries involve such fundamentally different mechanisms and surgical effort, AGIs are often used in advanced glaucomas with a high IOP, wheras AIT is commonly performed in mild glaucomas with straightforward access to the TM. We expanded our practice pattern to use AIT as a first surgery even for uncontrolled glaucomas often reserved for AGI because our studies suggested that AIT can be used after failed trabeculectomy, 7 in narrow angles 32, 33 and more severe glaucoma. 19, 20 The success rate of AIT at final follow-up was 68% matching previous reports with the same definition of success. [34] [35] [36] [37] AGI was successful in 62% of patients at the final follow-up consistent with reported success rates ranging from 35% to 85%. [38] [39] [40] [41] [42] In AGI we observed a relatively sharp decline of the success rate during the early postoperative period. It is common for the IOP after Ahmed glaucoma valve implantation to go through 2 phases: a relative hypotensive phase that occurs immediately after the surgery and lasts for at least 1 week, followed by an increase in IOP, termed the hypertensive phase, that starts at 1 to 6 weeks after surgery and is believed to be an early sign of failure. 43 Five-year data from the Ahmed Baerveldt Comparison study 44 showed a relatively early decline of success 85% during the early postoperative period followed by much slower trend toward 56% at the end of follow-up.
Although more reoperations were required in AGI, this study was not designed nor powered to detect significant differences in complication rates. The final IOP achieved here in AIT and reduction of medications is similar to the mean of the largest AIT series (n = 4659), in which the mean IOP fell from 23.1 to 16.2 after 12 months (30% decrease) on 0.7 fewer medications. 45 Analysis of both the degree of VF loss and the GI revealed no statistical difference in glaucoma severity between the 2 groups. The additional data presented here beyond the focus of 1-year outcomes suggest that both procedures remain comparable for ∼2.5 years.
Survival analysis is helpful to detail how much IOP data are being censored, for instance when IOP data are no longer included in the mean IOP because of a second surgery. In 1 study on AIT (n = 246), the mean final IOP after 4 years was 12 mm Hg (45% decrease from baseline) on 0.5 fewer medications, yet paradoxically, the authors recommended trabectome should only be used when the goal IOP is > 21 mm Hg. 14, 46 The main reason was the guarded success rates because only 64% of cases met TVT success criteria 29 after 1 year and only 28% were successful using an IOP cutoff of 18 mm Hg. In contrast, our study showed no statistically significant difference between the success rates for both groups. Compared with our success rate, the Ahmed versus Baerveldt comparison study (ABC) trial reported a higher success rate of 84% for AGI at 1 year. Likely the main reason why AIT has never been reported to be more successful than penetrating surgery is that both trabeculectomy and aqueous shunts bypass not only the site of the highest resistance to aqueous outflow in the TM, but also the proximal collector channel pathway that may harbor an additional outflow resistance. We applied a Cox hazard model to estimate the effects of covariates. At least 10 to 15 observations are needed for each parameter fit in a regression model to prevent overfitting. 47 Given the ∼60 eyes in these data set after matching, this directed us to attempt to fit no more than 4 to 6 covariates, but because of the number of failures in the survival analysis, only 2 to 3 covariates could be attempted to fit. We assumed a priori that baseline IOP would affect the outcome of surgery because at a minimum the IOP threshold for failure depended on the preoperative IOP. Therefore, a Cox proportional hazards model should at least model a linear relationship between baseline IOP and subsequent surgical failure while additional degrees of freedom would be desirable. Our previous studies indicated that the effect of previous cataract surgery is extremely limited or absent 26, 27 even in narrow angles. 33 Because of the limited number of eyes in this analysis, we only modeled IOP.
It is perhaps surprising that AGIs, which bypass the conventional outflow tract, did not lead to a significantly lower IOP on fewer medications than AIT, which relies on a functioning outflow system downstream of the ablated TM. Recent discoveries of segmental, 36,37 circumferential flow, [38] [39] [40] and discoveries of valve-like elements in collector channels 4, 41 highlight the complexity of the conventional outflow route. The advantage of tube shunts to bypass those is likely negated by the fibrosis and chronic foreign body reaction to a silicone drainage implant that is patient-specific and causes a variable diffusion barrier. 42 Because a conjunctival bleb and an implant are avoided entirely in AIT, it may be considerably safer than either trabeculectomy 43 or aqueous shunts. Complications in the ABC required intervention in 42% of Baerveldt glaucoma drainage devices and 26% of AGIs. 44 The rate of endophthalmitis in a large series of 542 aqueous shunts was 1.7%. 45 Endophthalmitis has only been reported once after AIT 46 and may approach the rate of this event in phacoemulsification (ie, 0.04% of 1 million cases). 47 In our study, AIT only had a single complication of cystoid macular edema. The rate of vision loss is also high: after 1 year, ≥ 2 Snellen lines of visual acuity were lost in 30% to 34% for both AGIs and Baerveldt implants in the ABC, Ahmed versus Baerveldt study, and TVT studies. The difference to our matched comparison is that those studies include more challenging glaucoma types, for instance, neovascular glaucoma and failed trabeculectomies or cataract surgery. Most of the AIT literature directly specifies that no patient in the study lost 2 lines of vision. There is a single study that noted that 13 patients (5%) lost > 2 lines of vision, but there is no clarification given specifying the reason for vision loss or whether those patients had received combined phaco-AIT versus standalone AIT. 14 Persistent hypotony is exceedingly rare. 6 The only patient in our study who lost > 2 Snellen lines of visual acuity was in the AGI group.
Limitations of this study were the modest number of AGI-only patients of a single surgeon (N.A.L.) that resulted in a limited recruitment window for the match. It is also important to recall that propensity score matching has to exclude highly different patient data sets to mimic randomization and reduce the bias of confounding variables. The actual use patterns will continue to include milder preglaucoma in AIT and complex multimechanism glaucomas with urgent IOP in AGI. Although propensity score matching tries to solely focus on the treatment effect, the results of this study do not mean that the effect would be equal in the patients at the end of the spectrum that could not be matched.
CONCLUSIONS
Using propensity score matching, AIT resulted in an IOP reduction, final IOP, and success rate at 1 year that is similar to AGI in groups of equivalent glaucoma severity. Results of this study will allow for the design of future comparative studies with crossover in the case of failure.
